Amicus Therapeutics Q3 revenue growth more than expected

Amicus Therapeutics

04/11/2025 12:10

Overview

Amicus Q3 2025 revenue grows 17% yr/yr, beating analyst expectations

Company achieves GAAP net income of $17 mln, reversing a loss from last year

Cash position increased by $33 mln in Q3 2025

Outlook

Amicus anticipates 2025 total revenue growth of 15% to 22%

Company expects Pombiliti + Opfolda revenue growth of 50% to 65% in 2025

Amicus projects positive GAAP net income in H2 2025

Result Drivers

GALAFOLD SALES - Galafold sales increased 15% yr/yr, driven by new patient starts and strong compliance

POMBILITI + OPFOLDA DEMAND - Sales for Pombiliti + Opfolda rose 45% yr/yr due to high demand and new launch countries

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$169 mln
$165.70 mln (9 Analysts)
Q3 EPS
$0.06
Q3 Net Income
$17 mln
Q3 Adjusted Operating Expenses
$95.40 mln
Q3 Operating Expenses
$115.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Amicus Therapeutics Inc is $15.50, about 42.8% above its November 3 closing price of $8.86

The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release: ID:nGNX4cMNFr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)